Supriya Lifescience Limited has announced that its board of directors will meet on Wednesday, May 27, 2026. The meeting has been convened in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The primary agenda for the meeting includes the consideration and approval of the audited financial results of the company for the quarter and financial year ended March 31, 2026. Additionally, the board will evaluate and recommend a dividend on the equity shares of the company for the financial year ended March 31, 2026, subject to the board's discretion.

Key Meeting Details

The following table outlines the key details regarding the upcoming board meeting:

Trading Window Closure

In compliance with the company's Code of Conduct for Prevention of Insider Trading, the trading window for dealing in the securities of the company by designated persons and their immediate relatives has been closed. This closure came into effect on April 1, 2026, and will remain in place until 48 hours after the declaration of the audited financial results on May 27, 2026.

Supriya Lifescience Limited has successfully completed a United States Food and Drug Administration (USFDA) inspection at its manufacturing facility located at Lote, Parshuram Industrial Area, Maharashtra, India. The inspection, conducted from February 2 to February 6, 2026, concluded with the issuance of a Form 483 containing one minor observation. The company has adequately addressed this observation and received the Establishment Inspection Report (EIR) indicating "Voluntary Action Indicated (VAI)", signifying a successful completion of the inspection.

Regulatory Disclosure and Compliance

The company has made this disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The official communication was sent to both BSE Limited and National Stock Exchange of India Limited on April 22, 2026, ensuring full transparency with regulatory authorities and stakeholders.

Understanding VAI Classification

The VAI rating indicates that while the inspection identified areas for improvement, these findings do not pose significant regulatory concerns. This classification suggests that the manufacturing facility maintains acceptable standards and compliance with FDA requirements, with only minor observations that can be addressed through voluntary corrective measures. The company has already adequately addressed the observation noted in the Form 483.

Regulatory Significance

For pharmaceutical manufacturers, USFDA inspections are critical regulatory milestones that assess compliance with Good Manufacturing Practices (GMP) and other quality standards. The successful completion of this inspection with a VAI rating demonstrates Supriya Lifescience's commitment to maintaining full compliance with current Good Manufacturing Practice (cGMP) requirements across all its manufacturing facilities.

The company's ability to navigate the USFDA inspection process with minimal issues reflects positively on its operational capabilities and quality management systems. This regulatory clearance supports the company's continued operations and potential market access for its pharmaceutical products in the US market.